There are currently 5176 ongoing clinical trials involving Leukemia
Of the 5176 trials,1394 trials are in Phase II
Furthermore, 1067 trials are in Phase III
The global pharmaceutical industry is steadily developing new drugs for Leukemia, an Oncology condition. The largest number of ongoing clinical trials for Leukemia is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Leukemia-related drug trials.
University of Texas MD Anderson Cancer Center: The leading ongoing Leukemia related clinical trial sponsor
University of Texas MD Anderson Cancer Center is the top sponsor for Leukemia-related ongoing clinical trials.
National Cancer Institute US, Novartis AG, Dana-Farber Cancer Institute Inc, AbbVie Inc, and City of Hope are among other notable clinical trial sponsors involved in Leukemia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Leukemia
Lenalidomide (Revlimid), Rituximab (MabThera, Rituxan, Ristova), and Ibrutinib (Imbruvica) are among the key marketed drugs involving Leukemia.
Lenalidomide (Revlimid) is a thalidomide analogue and an immunomodulatory imide drug (IMiD). It functions via the Protein cereblon (CRBN) Activator mechanism of action. It is formulated as hard gelatin capsules for the oral route of administration. Revlimid in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM), as maintenance therapy in patients with multiple myeloma following autologous hematopoietic stem cell transplantation ( auto-HSCT), is indicated for the treatment of patients with transfusion-dependent anemia due to low -or intermediate -1- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities, indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. Lenalidomide was first approved in 2005 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Celgene Corp.
Rituximab (MabThera, Rituxan, Ristova) is an anti-neoplastic agent. It functions via Cytotoxic to Cells Expressing B Lymphocyte Antigen CD20 mechanism of action. It is formulated as an injectable concentrate for solution for intravenous route and solution for the subcutaneous route of administration. Rituximab intravenous formulation is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy; as maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. Rituximab was first approved in 1997 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Genentech USA Inc.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward